Clinical Trial

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-15
Trial Details
NCT Number NCT07668388
Lead Sponsor Novo Nordisk A/S
Conditions Diabetes Mellitus, Type 2
Enrollment 300 participants
Start Date 2026-06-22
Primary Completion 2027-10-04 (estimated)
Study Completion 2027-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-14